195 related articles for article (PubMed ID: 22489922)
1. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity.
Slowik M; Urbaniak-Kujda D; Bohdanowicz-Pawlak A; Kapelko-Slowik K; Dybko J; Wolowiec D; Jazwiec B; Daroszewski J
Endocr Res; 2012; 37(2):89-95. PubMed ID: 22489922
[TBL] [Abstract][Full Text] [Related]
2. [A study of cytokine expression in peripheral blood of patients with Graves' ophthalmopathy].
Tang L; Luo Q; Zhou X; Xia R
Zhonghua Yan Ke Za Zhi; 2002 Mar; 38(3):165-7. PubMed ID: 11955323
[TBL] [Abstract][Full Text] [Related]
3. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
Salvi M; Girasole G; Pedrazzoni M; Passeri M; Giuliani N; Minelli R; Braverman LE; Roti E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2976-9. PubMed ID: 8768861
[TBL] [Abstract][Full Text] [Related]
4. Increased percentage of L-selectin+ and ICAM-1+ peripheral blood CD4+/CD8+ T cells in active Graves' ophthalmopathy.
Pawlowski P; Mysliwiec J; Stasiak-Barmuta A; Bakunowicz-Lazarczyk A; Gorska M
Folia Histochem Cytobiol; 2009; 47(1):29-33. PubMed ID: 19419934
[TBL] [Abstract][Full Text] [Related]
5. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
6. M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor.
Lu Y; Wang Y; Wang Y; Wu Y; Huang Y; Liu X; Zhang S; Zhong S; Li Y; Li B; Sun J; Fang S; Zhou H
Thyroid; 2023 Mar; 33(3):338-350. PubMed ID: 36617890
[No Abstract] [Full Text] [Related]
7. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
Wierzbowska A; Urbańska-Ryś H; Robak T
Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
[TBL] [Abstract][Full Text] [Related]
8. CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy.
Xia N; Zhou S; Liang Y; Xiao C; Shen H; Pan H; Deng H; Wang N; Li QQ
Int J Mol Med; 2006 May; 17(5):911-6. PubMed ID: 16596280
[TBL] [Abstract][Full Text] [Related]
9. Association of Graves' disease and prevalence of circulating IFN-gamma-producing CD28(-) T cells.
Sun Z; Zhong W; Lu X; Shi B; Zhu Y; Chen L; Zhang G; Zhang X
J Clin Immunol; 2008 Sep; 28(5):464-72. PubMed ID: 18704663
[TBL] [Abstract][Full Text] [Related]
10. Release of interleukin-6 and its soluble receptors by activated peripheral blood monocytes is elevated in hypocholesterolemic hemodialysis patients.
Tsirpanlis G; Chatzipanagiotou S; Boufidou F; Kordinas V; Alevyzaki F; Zoga M; Kyritsis I; Ioannou D; Fatourou A; Nicolaou C
Am J Nephrol; 2005; 25(5):484-90. PubMed ID: 16127269
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
12. [The influence of corticosteroids on IL-6/IL-6R system in patients with Graves' ophthalmopathy].
Myśliwiec J; Kretowski A; Topolska J; Stepień A; Kinalska I
Pol Arch Med Wewn; 2002 Aug; 108(2):739-44. PubMed ID: 12476893
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking.
Salvi M; Pedrazzoni M; Girasole G; Giuliani N; Minelli R; Wall JR; Roti E
Eur J Endocrinol; 2000 Aug; 143(2):197-202. PubMed ID: 10913938
[TBL] [Abstract][Full Text] [Related]
14. IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients.
Stelmasiak Z; Kozioł-Montewka M; Dobosz B; Rejdak K
Med Sci Monit; 2001; 7(5):914-8. PubMed ID: 11535934
[TBL] [Abstract][Full Text] [Related]
15. [Serum IL-1 receptor antagonist and IL-1beta in patients with Graves' opthalmopathy].
Xie Q; Li SQ; Aa ZM; Wei SQ; Zhao HL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):238-41. PubMed ID: 16608084
[TBL] [Abstract][Full Text] [Related]
16. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.
Vannucchi G; Campi I; Bonomi M; Covelli D; Dazzi D; Currò N; Simonetta S; Bonara P; Persani L; Guastella C; Wall J; Beck-Peccoz P; Salvi M
Clin Exp Immunol; 2010 Sep; 161(3):436-43. PubMed ID: 20529087
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T-cells in Graves' orbitopathy: baseline findings and immunomodulation by anti-T lymphocyte globulin.
Kahaly GJ; Shimony O; Gellman YN; Lytton SD; Eshkar-Sebban L; Rosenblum N; Refaeli E; Kassem S; Ilany J; Naor D
J Clin Endocrinol Metab; 2011 Feb; 96(2):422-9. PubMed ID: 21147887
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter.
Bossowski A; Urban M
J Pediatr Endocrinol Metab; 2001 Jun; 14(6):741-7. PubMed ID: 11453524
[TBL] [Abstract][Full Text] [Related]
19. [Study on serum soluble interleukin-6 receptor levels in patients with malignant hematological diseases].
Li D; Yang J; Cui W; Ma C; Ma C; Ji E; Li J; Li G; Ma C
Zhonghua Xue Ye Xue Za Zhi; 1997 Nov; 18(11):577-80. PubMed ID: 15625895
[TBL] [Abstract][Full Text] [Related]
20. Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia.
Goette NP; Lev PR; Heller PG; Glembotsky AC; Chazarreta CD; Salim JP; Molinas FC; Marta RF
Exp Hematol; 2010 Oct; 38(10):868-876.e1. PubMed ID: 20600579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
